Antibody-Drug Conjugate Cuts Death Risk by 54% in Relapsed Small-Cell Lung Cancer
The phase III TAISHAN-302 trial found that the anti-B7-H3 antibody-drug conjugate Tam-Peli reduced the risk of death by 54 percent ...
The phase III TAISHAN-302 trial found that the anti-B7-H3 antibody-drug conjugate Tam-Peli reduced the risk of death by 54 percent ...
A meta-analysis of six randomized trials found that adding PD-1/PD-L1 inhibitors to chemotherapy was associated with longer progression-free and overall ...
A prespecified interim analysis of the phase 3 HARMONi-2 trial shows ivonescimab achieved median overall survival of 30.8 months versus ...
A retrospective cohort of 163 patients treated at one Rwandan cancer center reported estimated median overall survival of 3.68 years ...
A retrospective study of 430 surgically treated patients links elevated inflammation, thyroid-related blood markers and selected immune-cell measures with survival ...
A retrospective study of 47 patients found that high folate receptor alpha expression was independently associated with shorter progression-free survival ...
A two-center retrospective cohort study of 823 surgically resected pulmonary neuroendocrine carcinoma patients found that a Transformer-based AI model achieved ...
A single-center cohort study linked checkpoint inhibitor-containing therapy with longer unadjusted progression-free survival in advanced SMARCA4-deficient thoracic tumors, but adjusted ...
A meta-analysis of fourteen retrospective cohort studies associates TACE-HAIC combined with targeted therapy and immune checkpoint inhibitors with improved survival ...
A retrospective cohort study of 194 patients with esophageal squamous cell carcinoma found that postoperative pathological lymph node stage, rather ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine